Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 161

1.

Evaluation of fluorine-18-BPA-fructose for boron neutron capture treatment planning.

Kabalka GW, Smith GT, Dyke JP, Reid WS, Longford CP, Roberts TG, Reddy NK, Buonocore E, Hübner KF.

J Nucl Med. 1997 Nov;38(11):1762-7.

2.

Evaluation of 4-borono-2-18F-fluoro-L-phenylalanine-fructose as a probe for boron neutron capture therapy in a glioma-bearing rat model.

Wang HE, Liao AH, Deng WP, Chang PF, Chen JC, Chen FD, Liu RS, Lee JS, Hwang JJ.

J Nucl Med. 2004 Feb;45(2):302-8.

3.
4.

Boron neutron-capture therapy (BNCT) for glioblastoma multiforme (GBM) using the epithermal neutron beam at the Brookhaven National Laboratory.

Chadha M, Capala J, Coderre JA, Elowitz EH, Iwai J, Joel DD, Liu HB, Wielopolski L, Chanana AD.

Int J Radiat Oncol Biol Phys. 1998 Mar 1;40(4):829-34.

PMID:
9531367
5.

The use of positron emission tomography to develop boron neutron capture therapy treatment plans for metastatic malignant melanoma.

Kabalka GW, Nichols TL, Smith GT, Miller LF, Khan MK, Busse PM.

J Neurooncol. 2003 Mar-Apr;62(1-2):187-95.

PMID:
12749713
6.

Boron neutron capture therapy (BNCT) for glioblastoma multiforme: a phase II study evaluating a prolonged high-dose of boronophenylalanine (BPA).

Henriksson R, Capala J, Michanek A, Lindahl SA, Salford LG, Franzén L, Blomquist E, Westlin JE, Bergenheim AT; Swedish Brain Tumour Study Group.

Radiother Oncol. 2008 Aug;88(2):183-91. doi: 10.1016/j.radonc.2006.04.015. Epub 2008 Mar 11.

PMID:
18336940
7.

Effect of dose and infusion time on the delivery of p-boronophenylalanine for neutron capture therapy.

Joel DD, Coderre JA, Micca PL, Nawrocky MM.

J Neurooncol. 1999 Feb;41(3):213-21.

PMID:
10359141
8.

Boron neutron capture therapy for glioblastoma multiforme using p-boronophenylalanine and epithermal neutrons: trial design and early clinical results.

Coderre JA, Elowitz EH, Chadha M, Bergland R, Capala J, Joel DD, Liu HB, Slatkin DN, Chanana AD.

J Neurooncol. 1997 May;33(1-2):141-52.

PMID:
9151231
9.

Positron emission tomography and [18F]BPA: a perspective application to assess tumour extraction of boron in BNCT.

Menichetti L, Cionini L, Sauerwein WA, Altieri S, Solin O, Minn H, Salvadori PA.

Appl Radiat Isot. 2009 Jul;67(7-8 Suppl):S351-4. doi: 10.1016/j.apradiso.2009.03.062. Epub 2009 Apr 2.

PMID:
19410471
10.

Distribution of BPA and metabolic assessment in glioblastoma patients during BNCT treatment: a microdialysis study.

Bergenheim AT, Capala J, Roslin M, Henriksson R.

J Neurooncol. 2005 Feb;71(3):287-93.

PMID:
15735919
11.

Positron emission tomography-based boron neutron capture therapy using boronophenylalanine for high-grade gliomas: part II.

Imahori Y, Ueda S, Ohmori Y, Sakae K, Kusuki T, Kobayashi T, Takagaki M, Ono K, Ido T, Fujii R.

Clin Cancer Res. 1998 Aug;4(8):1833-41.

12.

PET pharmacokinetic analysis to estimate boron concentration in tumor and brain as a guide to plan BNCT for malignant cerebral glioma.

Nariai T, Ishiwata K, Kimura Y, Inaji M, Momose T, Yamamoto T, Matsumura A, Ishii K, Ohno K.

Appl Radiat Isot. 2009 Jul;67(7-8 Suppl):S348-50. doi: 10.1016/j.apradiso.2009.03.061. Epub 2009 Mar 27.

PMID:
19375930
13.

Biodistribution of p-boronophenylalanine in patients with glioblastoma multiforme for use in boron neutron capture therapy.

Elowitz EH, Bergland RM, Coderre JA, Joel DD, Chadha M, Chanana AD.

Neurosurgery. 1998 Mar;42(3):463-8; discussion 468-9.

PMID:
9526978
14.

Comments to article: Henriksson R et al., Boron neutron capture therapy (BNCT) for glioblastoma multiforme: a phase II study evaluating a prolonged high-dose of boronophenylalanine (BPA) Radiother Oncol (2008).

H-Stenstam B.

Radiother Oncol. 2008 Aug;88(2):287-8; author reply 288. doi: 10.1016/j.radonc.2008.05.026. Epub 2008 Jul 9. No abstract available.

PMID:
18617284
15.

Improved survival after boron neutron capture therapy of brain tumors by Cereport-mediated blood-brain barrier modulation to enhance delivery of boronophenylalanine.

Yang W, Barth RF, Bartus RT, Rotaru JH, Moeschberger ML, Ferketich AK, Nawrocky MM, Coderre JA, Goodman JH.

Neurosurgery. 2000 Jul;47(1):189-97; discussion 197-8.

PMID:
10917362
16.

Boron neutron capture therapy of brain tumors: clinical trials at the finnish facility using boronophenylalanine.

Joensuu H, Kankaanranta L, Seppälä T, Auterinen I, Kallio M, Kulvik M, Laakso J, Vähätalo J, Kortesniemi M, Kotiluoto P, Serén T, Karila J, Brander A, Järviluoma E, Ryynänen P, Paetau A, Ruokonen I, Minn H, Tenhunen M, Jääskeläinen J, Färkkilä M, Savolainen S.

J Neurooncol. 2003 Mar-Apr;62(1-2):123-34.

PMID:
12749708
17.

Boron neutron capture therapy of brain tumors: enhanced survival and cure following blood-brain barrier disruption and intracarotid injection of sodium borocaptate and boronophenylalanine.

Barth RF, Yang W, Rotaru JH, Moeschberger ML, Boesel CP, Soloway AH, Joel DD, Nawrocky MM, Ono K, Goodman JH.

Int J Radiat Oncol Biol Phys. 2000 Apr 1;47(1):209-18.

PMID:
10758326
18.

Macro- and microdistributions of boron drug for boron neutron capture therapy in an animal model.

Lin YC, Hwang JJ, Wang SJ, Yang BH, Chang CW, Hsiao MC, Chou FI.

Anticancer Res. 2012 Jul;32(7):2657-64.

PMID:
22753723
20.

Biodistribution of boronophenylalanine in patients with glioblastoma multiforme: boron concentration correlates with tumor cellularity.

Coderre JA, Chanana AD, Joel DD, Elowitz EH, Micca PL, Nawrocky MM, Chadha M, Gebbers JO, Shady M, Peress NS, Slatkin DN.

Radiat Res. 1998 Feb;149(2):163-70.

PMID:
9457896

Supplemental Content

Support Center